931 results about "Umbilical cord" patented technology

The invention provides an exosome, a mesenchymal stem cell and application of the exosome and the mesenchymal stem cell in treatment of type 2 diabetes mellitus, and belongs to the technical field of biological medicine. The exosome secreted by the umbilical cord mesenchymal stem cells of the composite pretreatment group is used for treating the type 2 diabetes mellitus, and the obvious advantages are shown. Compared with a model control group, the exosome has the advantages that the glucose tolerance of diabetic rats treated by the exosome is obviously improved, the blood glucose value is reduced by about 47.5% within 120 minutes, the area under a blood glucose curve (AUC) is reduced by about 50.5%, the serum insulin is increased by about 147.7%, insulin secretion is effectively promoted, the glycosylated hemoglobin level is obviously reduced, and the long-term blood glucose control effect is good. By integrating various indexes, the exosome obtained by the composite pretreatment scheme provided by the invention has a remarkable effect of improving the illness state of rats with type 2 diabetes mellitus, provides a new effective strategy for treatment of type 2 diabetes mellitus, and shows a good application prospect.

The invention discloses a polypeptide for promoting proliferation of human umbilical cord mesenchymal stem cells and application of the polypeptide in in-vitro culture of the human umbilical cord mesenchymal stem cells. The mesenchymal stem cells have all characteristics of stem cells, have self-renewal and multidirectional differentiation potentials, and can be differentiated into various mesenchymal tissues, such as bones, cartilages, fat and the like. How to rapidly proliferate the human umbilical cord mesenchymal stem cells in vitro so as to rapidly obtain enough seed cells in a short time has important significance. The invention provides a polypeptide with a sequence as shown in Sequence NO.1. The polypeptide has an obvious effect of promoting in-vitro proliferation of human umbilical cord mesenchymal stem cells, does not change phenotypes of the human umbilical cord mesenchymal stem cells, and can be used for in-vitro efficient amplification of the human umbilical cord mesenchymal stem cells.

The invention relates to the technical field of NK cell culture, and discloses a serum-free medium for NK cells from umbilical cord blood after cryopreservation and a culture method thereof.The medium comprises a coating solution, an induction medium and an amplification medium; wherein the coating liquid is prepared from an anti-CD16 monoclonal antibody and DPBS (diphenylphosphonic acid); the induction culture medium comprises a basic culture medium, a human-derived platelet lysate and cell factors IL-15, IL-18 and IL-21; the amplification culture medium comprises a basic culture medium, a human-derived platelet lysate and IL-2. The culture method comprises the following steps: obtaining mononuclear cells from fresh umbilical cord blood, and then cryopreserving and resuscitating; and carrying out multiplication culture on the recovered umbilical cord blood mononuclear cells by using the serum-free culture medium. According to the NK cell culture medium, the NK cells with high purity, high killing activity and high cytotoxic activity can be obtained without autoserum culture.

The invention relates to the technical field of biological medicines, in particular to an umbilical cord mesenchymal stem cell exosome and application of the umbilical cord mesenchymal stem cell exosome in preparation of a medicine for treating male infertility caused by hidden testis. The prepared high-concentration umbilical cord mesenchymal stem cell exosome suspension preparation is directly used for treating cultured spermatogonial cells and spermatoblasts in vitro, is injected into the testis of a mouse, and is used for improving the seminiferous tubule and spermatogenic microenvironment of testis tissue and promoting division and proliferation of the spermatogonial cells and the spermatoblasts. The method can effectively reverse oligospermia and azoospermia caused by the hidden testis, and compared with a model without intervention of treatment means, the method can effectively promote increase and even regeneration of sperms in the testis.

The invention provides application of an enhanced and optimized mesenchymal stem cell exosome in knee osteoarthritis and muscle cartilage injury, and belongs to the technical field of biological medicine. The treatment activity of the umbilical cord mesenchymal stem cell exosome is remarkably improved by combining a composite pretreatment technology with a 3D culture system. Through the synergistic effect of the total flavonoids of rhizoma drynariae and tanshinone IIA, the pathological process of knee osteoarthritis can be regulated and controlled in multiple dimensions, including inflammatory reaction inhibition, cartilage repair promotion and joint function improvement, and the functional limitation of single-component pretreatment is broken through. The invention provides a safe and efficient novel treatment technical strategy for relieving knee osteoarthritis and muscle cartilage injury, and has a wide clinical application prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to an umbilical cord mesenchymal stem cell preparation and application thereof to treatment of hepatic diseases. The umbilical cord mesenchymal stem cell preparation comprises umbilical cord mesenchymal stem cells from the third generation to the sixth generation, a GPR55 peptide conjugate and pharmaceutically acceptable auxiliary materials. And the amino acid sequence of the GPR55 peptide conjugate is selected from CKKNSPTLC, CKKNTPTQC or CKKNSPTGC. The umbilical cord mesenchymal stem cell preparation can obviously reduce alpha-SMA and COL-I secreted by hepatic stellate cells and inhibit activation of the hepatic stellate cells, and the fact that the umbilical cord mesenchymal stem cell preparation has anti-hepatic fibrosis activity is further verified in a CCl4 induced hepatic fibrosis model.

The invention relates to a medicine, a medicine composition and application of the medicine and the medicine composition in treatment of liver fibrosis. The medicine and the medicine composition comprise an umbilical cord mesenchymal stem cell membrane; the umbilical cord mesenchymal stem cell membrane is prepared by the following steps: coating the surface of a temperature-sensitive culture dish with a matrix; adding the cell suspension of the umbilical cord mesenchymal stem cells into a temperature-sensitive culture dish for culturing; the temperature is reduced, the umbilical cord mesenchymal stem cells and the extracellular matrix secreted by the umbilical cord mesenchymal stem cells are separated in a lamellar mode, and the umbilical cord mesenchymal stem cell membrane is obtained. The medicine and the medicine composition provided by the invention can effectively relieve liver fibrosis.

The invention discloses a cord blood-derived regulatory T cell amplification culture medium and a use method thereof, and relates to the field of animal cell culture and immune cell therapy, the culture medium is a serum-free culture medium, the culture medium is composed of a basic culture medium, a serum substitute combination, a combination of four cell factors, an immunosuppressor, an apparent stabilizer and an antioxidant, and all the components play a role synergistically; according to the use method, cell amplification is realized through a collaborative process of staged environmental regulation and targeted activation. According to the method, the problems of exogenous pollution and batch difference caused by dependence of a serum-containing system on cord blood-derived regulatory T cell amplification in the prior art are solved, the defect that a serum-free scheme is difficult to consider the amplification efficiency and the function stability at the same time is overcome, the cell amplification quality and the clinical application safety are guaranteed, and the method is suitable for large-scale clinical transformation requirements.

The invention discloses a stem cell exosome based on targeted fusion polypeptide modification, a preparation method and application of the stem cell exosome in treating male erectile dysfunction. According to the exosome, a specific targeting fusion polypeptide (sequence: EPLQLKM-GGGS-DPPV) is anchored on the surface through a chemical coupling technology, so that the targeting property of the exosome on cavernosum smooth muscle cells is enhanced; meanwhile, an anti-TrkA monoclonal antibody (TrkA-2E7-HL) is loaded through an electroporation method, and a fibrosis pathway mediated by a nerve growth factor (NGF) is inhibited. The exosome induces secretion of the umbilical cord mesenchymal stem cells by adopting an anti-oxidation culture medium, so that the anti-oxidation activity of the exosome is remarkably improved. Experiments show that in a diabetes ED rat model, the erectile function (ICP / MAP ratio) of the modified exosome is improved to 0.79 + / -0.05, the fibrosis area is reduced to 9.2 + / -1.6%, and the NO secretion level is improved by 3.5 times compared with that of a common exosome. Through triple mechanisms of polypeptide targeting, antibody synergy and oxidation resistance, effective reversion of the ED pathological process is realized, and the polypeptide has remarkable novelty and clinical transformation potential.

The invention discloses a therapeutic nano-vesicle preparation rich in mitochondrial functional protein, a preparation method of the therapeutic nano-vesicle preparation and application of the therapeutic nano-vesicle preparation in treatment of radioactive skin injury. The preparation method comprises the following steps: culturing, amplifying and cleaning umbilical cord mesenchymal stem cells, dispersing the umbilical cord mesenchymal stem cells in a suspension, mechanically extruding the umbilical cord mesenchymal stem cells into a crude solution through a multistage aperture polycarbonate membrane, and centrifuging, concentrating and purifying the crude solution to obtain the preparation. The preparation has the remarkable advantages that local administration can be realized, inflammation can be quickly inhibited, oxidative stress is reduced, and a repair pathway is activated, so that the preparation is suitable for treating acute radioactive skin injury; the preparation method is easy to standardize and scale, high in stability and convenient for emergency storage and delivery, and avoids the defects of cell therapy; a plurality of targets such as immune inflammation, oxidative stress and the like can be synergistically regulated, the biological effect of hUMSCs is simulated and partially replaced, and the limitation caused by the cell survival rate and the microenvironment dependency is avoided; the key function of hUMSCs is covered in function, and the clinical feasibility, safety and emergency suitability of the application level are higher.

The invention relates to the technical field of stem cell injections, in particular to a human umbilical cord mesenchymal stem cell injection and a preparation method thereof. The cell cryoprotectant comprises the following components: a cell cryoprotectant and P6-generation human umbilical cord mesenchymal stem cells. By selecting P6-generation human umbilical cord mesenchymal stem cells, the capacity of secreting hepatocyte growth factors (HGF) can be improved; the cell cryoprotectant contains 6-9wt% of dimethyl sulfoxide and a certain amount of human serum albumin, can better protect cells and maintain the motility rate and biological functions of the cells, and is more beneficial to preparation of cryopreserved human umbilical cord mesenchymal stem cell injection. The P6-generation human umbilical cord mesenchymal stem cells are obtained by culturing a culture medium containing fetal calf serum, and the ability of the injection to repair liver injury can be improved.

The invention belongs to the technical field of biological medicines, and particularly relates to an umbilical cord mesenchymal stem cell preparation and application thereof in treating prostate diseases. According to the umbilical cord mesenchymal stem cell preparation, the umbilical cord mesenchymal stem cells of the third generation to the sixth generation and the neurofilament peptide serve as active components, pharmaceutically acceptable auxiliary materials are matched, the prostate index can be remarkably reduced, the concentration of PACP and SRD5A2 can be reduced, and the umbilical cord mesenchymal stem cell preparation has a remarkable curative effect on prostatic hyperplasia. And the umbilical cord mesenchymal stem cells of the third generation to the sixth generation and the neurofilament peptide supplement each other and have a synergistic effect, so that a remarkable progress is generated.

The invention provides an establishment method of umbilical cord mesenchymal stem cells with high expression of IGF-1 (Insulin-like Growth Factor 1) and application of the umbilical cord mesenchymal stem cells in premature ovarian failure. The construction method of the umbilical cord mesenchymal stem cells with high expression of IGF-1 comprises the step of transfecting the umbilical cord mesenchymal stem cells with the IGF-1 gene, so that the umbilical cord mesenchymal stem cells highly express IGF-1. The invention also provides application of the umbilical cord mesenchymal stem cell with high expression of IGF-1 in preparation of drugs for treating premature ovarian failure. According to the invention, the IGF-1 gene is transfected to the hUC-MSC, so that the hUC-MSC highly expresses the IGF-1, and the hUC-MSC secretes a large amount of IGF-1. The ovarian function is improved through the immunoregulation effect of hUC-MS, and meanwhile, the effect of resisting apoptosis of granular cells is achieved through IGF-1 secreted by hUC-MS. And the treatment effect on the premature ovarian failure is achieved through synergism of the two effects.

The invention discloses a method for increasing the yield of mesenchymal stem cell exosomes. A main culture medium used in the method is a human umbilical cord mesenchymal stem cell serum-free culture medium, and different natural compounds are respectively added in three main stages of mesenchymal stem cell growth, namely a recovery stage, an amplification stage and a stable stage, so that the characteristics of the mesenchymal stem cells in the stages are pertinently improved; the survival rate of the mesenchymal stem cells is protected in stages, the amplification efficiency of the mesenchymal stem cells is improved, the stability of the mesenchymal stem cells is maintained, and the exosome secretion amount of the mesenchymal stem cells can be remarkably increased through combined use of the three natural compounds. According to the invention, the secretion amount of the exosome of the mesenchymal stem cells can be obviously increased, and the problem of low yield of the mesenchymal stem cells at present is solved.

The invention discloses a method for culturing CIK (Cytokine-Induced Killer) cells and application thereof. The method comprises the following steps: recovering cord blood, mixing and centrifuging the recovered cord blood and a buffer solution, re-suspending and precipitating, centrifuging again to obtain cord blood mononuclear cells, inoculating the cord blood mononuclear cells into an activation culture medium, and culturing to obtain the CIK cells, the buffer solution contains L-proline, human recombinant DNA enzyme and angelica polysaccharide. According to the method, the mononuclear cells can be separated from the umbilical cord blood preserved by liquid nitrogen, the utilization rate of the umbilical cord blood which can only be discarded due to insufficient cells is increased, the traditional lymphocyte separation process is optimized, the recovery rate of the mononuclear cells is increased, and the cost is reduced. The method provided by the invention can be used for culturing dozens to ten billions of CIK cells from a small amount of cryopreserved cord blood, and has huge advantages in the field of CIK cell culture and application.

The invention relates to a leukocyte extract extraction and purification method, and belongs to the field of biology. Specifically, animal umbilical cord blood is selected as a raw material, a leukocyte extract is obtained through a series of extraction and purification steps, and polypeptide shown in SEQ ID NO.1-2 is obtained through further separation; the leukocyte extract and polypeptide prepared by the invention have remarkable antioxidant and anti-wrinkle effects and can be used for preparing medicines or cosmetics with special effects, and the application prospect of the leukocyte extract is expanded.

The invention provides a small extracellular vesicle composite collagen hydrogel injection, and belongs to the technical field of osteoarthritis, and the small extracellular vesicle composite collagen hydrogel injection is prepared by the following steps: S1, mixing a sodium alginate solution with a type I collagen solution to obtain a mixed solution, adding a CaCl2 solution into the mixed solution to form gel, adding an FGF18 solution into the gel, and mixing to obtain FGF18 sodium alginate / collagen hydrogel; s2, transfecting a Lenti-IGF-1-EGF lentiviral vector to P3 generation human umbilical cord mesenchymal stem cells, culturing to obtain P5 generation IGF-1 overexpressed MSCs cells, namely P5 generation IGF-1-MSCs cells, co-culturing with the P5 generation IGF-1-MSCs cells by using curcumin, and separating and extracting a small extracellular vesicle solution rich in curcumin; and S3, mixing the small extracellular vesicle solution rich in curcumin with the FGF18 sodium alginate / collagen hydrogel, so as to obtain the small extracellular vesicle composite collagen hydrogel injection. The invention provides a small extracellular vesicle composite collagen hydrogel injection, which achieves the purposes of relieving inflammatory injury of osteoarthritis and enhancing the treatment effect of osteoarthritis.

The invention discloses a ready-to-use activated human umbilical cord mesenchymal stem cell as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out passage on P0-generation cells for three times to obtain P3-generation cells; cryopreserving P3 generation cells, and establishing a cell seed bank; resuscitating the cells in the seed bank for three times of passage to obtain P6-generation cells; and carrying out activation culture on the P6-generation cells, and resuspending the activated P6-generation cells in a cell protective agent to obtain the human umbilical cord mesenchymal stem cell original suspension. The invention also discloses an umbilical cord mesenchymal stem cell cryopreservation preparation. The cryopreservation preparation is obtained by mixing the human umbilical cord mesenchymal stem cell original suspension with a cryopreservation protective agent, sub-packaging and cryopreserving. Experiments prove that the human umbilical cord mesenchymal stem cell cryopreserved preparation prepared by the invention can be stored for a long time, is convenient to store, transport and use clinically, can complete effectiveness and safety index detection within the shelf life, and has the same activity as a fresh preparation.

The invention relates to the technical field of biomedicine, in particular to a method for efficiently separating and preparing exosomes, which comprises the following steps: S10, providing human umbilical cord mesenchymal stem cells; s20, culturing the human umbilical cord mesenchymal stem cells by using an exosome induction culture medium; the exosome induction culture medium contains a first inflammatory factor; a second inflammatory factor is added in the culture process; the first inflammatory factor comprises at least one selected from the following groups: IL-6 and TNF-alpha; the second inflammatory factor comprises CCL2; and S30, collecting the supernatant of the culture medium in the step S20, and centrifugally collecting to obtain the exosome. The method can improve the yield of the exosomes, has the advantage of simple operation, is suitable for extracting a large amount of exosomes, and has a good clinical application prospect.

The invention discloses a preparation method and application of an umbilical cord extract for improving and repairing hair follicle miniaturization. The preparation method of the umbilical cord extract comprises the following steps: washing an animal umbilical cord, cutting the animal umbilical cord into pieces, digesting the animal umbilical cord with pancreatin, adding a serum-free mesenchymal stem cell culture medium, blowing and beating to disperse tissues, filtering, performing low-energy red light irradiation on the filtered tissue fluid, incubating for 10-12 hours, adding the serum-free mesenchymal stem cell culture medium with the same volume, continuously incubating for 48-72 hours, and performing freeze drying to obtain the umbilical cord extract. And adding an isometric serum-free mesenchymal stem cell culture medium, adding mir-135b at the same time, treating for 48-72 hours, taking out tissue fluid, performing freeze thawing, ultrasonic treatment and filtration, and diluting filtrate with sterile water to obtain the serum-free mesenchymal stem cell culture medium. The umbilical cord extract can remarkably improve and repair miniaturized hair follicles and promote the diameter of hair to recover to normal, can be used as a novel raw material, and is used for preparing cosmetics and medicines with the effects of improving and repairing the miniaturized hair follicles, promoting hair growth or preventing alopecia.

The invention is suitable for the technical field of biological medicine, and provides an excess drug treatment cell as well as a preparation method and application thereof. According to the invention, human umbilical cord mesenchymal stem cells (H.P.M) treated by excessive prednisone (PRED) are used as a carrier of PRED, and the excessive PRED treatment enables the human umbilical cord mesenchymal stem cells to lose proliferation ability and activity, but retains the ability of the human umbilical cord mesenchymal stem cells to target an inflammation site. The H.P.M can accurately deliver PRED to an inflammation part, so that pH-sensitive controlled release is realized, the treatment effect is improved, and the side effect of systemic application of PRED is greatly reduced. Due to the good drug loading capacity and release stability, the effectiveness and stability of drug delivery are further improved. The excess drug treatment method can be applied to other types of cells, and other drugs can be selected as the excess drug for treating the cells, so that a breakthrough is brought to treatment of gouty arthritis, and a new way is opened up for treatment of other diseases.

The invention provides a tightening and repairing gynecological gel. Preparation raw materials comprise carbomer, sodium hyaluronate, an animal umbilical cord extract, madecassoside, carnosine, a polygonum cuspidatum root extract, a scutellaria baicalensis root extract, a tea leaf extract, a chamomile flower extract, elastic collagen, arginine, pentanediol, butanediol, glycerin, p-hydroxyacetophenone, capryloyl hydroximic acid and purified water. The gynecological gel can maintain balanced strains, so that the microenvironment of the vagina is kept normal; vaginal atrophy is improved, the tight state of the vagina is recovered, and vaginal dryness is relieved; damaged mucosa can be repaired, the natural defense function of women is enhanced, and gynecological infection is prevented. The gynecological gel has good biocompatibility, cell affinity and mechanical properties, and can supplement collagen to female private parts, repair damaged vaginal mucosa and promote wound healing; the vagina can be moisturized and moistened, the looseness and dryness of the vagina are improved, the micro-ecological balance of the vagina is adjusted, and the immunity of a female reproductive system is improved.

The invention discloses application of a stem cell exosome in treating depression-like behaviors caused by high-altitude hypoxia, and belongs to the technical field of biomedicine. The stem cell exosome is an exosome derived from human umbilical cord mesenchymal stem cells, and is used for drugs for preventing and / or treating depression-like behaviors caused by high-altitude hypoxia. The exosome can effectively improve depression-like core behavior symptoms caused by high-altitude hypoxia by regulating a brain-intestinal axis; the method starts from remodeling intestinal flora so as to influence the intracerebral metabolite spectrum, and finally plays a role in neuroprotection by regulating and controlling a 5-HT6 / cAMP-PKA key signal channel. In addition, the combination of the hUC-MSC-exo and probiotics shows synergistic interaction potential, and a potential treatment strategy which is novel in mechanism, remarkable in effect and high in safety is provided for the field.

The invention discloses a cord blood-derived hematopoietic stem cell as well as an amplification method and application thereof. The method comprises the step of culturing umbilical cord blood mononuclear cells by using a culture medium containing thymus active polypeptide, stem cell growth factors and heat shock protein. According to the method for amplifying the umbilical cord blood-derived hematopoietic stem cells, the proliferation efficiency of umbilical cord blood mononuclear cells can be remarkably improved, and the amplification capacity of umbilical cord blood immune cells (NK cells) is improved by more than 5 times compared with that of a traditional method.

The invention relates to the technical field of cell drug preparation process optimization, in particular to an umbilical cord stem cell drug preparation parameter optimization method utilizing machine learning, which comprises the following steps: preprocessing to generate a control input time sequence and an observation output time sequence, and forming a process instruction library; constructing an intervening state space model based on the two types of time sequences, and assimilating the intervening state space model; defining multiple targets and constraints, compiling a process, simulating on the model, determining a feasible region by combining statistical calibration and formalized verification, and generating a feasibility judgment function; and carrying out microparameterization on the process in the feasible region and optimizing under constraints, carrying out rolling solution according to a preset prediction window in the model prediction control framework, outputting an optimal process flow and a monitoring threshold value, and executing record backflow updating. According to the method, the replicability, the compliance and the cross-batch robustness of the process are enhanced.

The invention relates to the technical field of biological medicines, in particular to an umbilical cord source mesenchymal stem cell exosome preparation, a preparation method and application in preparation of osteoarthritis medicines. The preparation is prepared by the method. The method comprises the following steps: pretreating umbilical cord-derived mesenchymal stem cells by adopting a pretreating agent; removing the pretreatment agent, and carrying out gradient centrifugation treatment on the pretreated umbilical cord source mesenchymal stem cells to obtain exosome precipitate; and re-suspending the exosome precipitate in a buffer solution containing a protease inhibitor to obtain the umbilical cord source mesenchymal stem cell exosome preparation. The application refers to the application of the preparation in preparation of osteoarthritis drugs. The problems of low yield and functional heterogeneity of EXO obtained by a conventional culture method are solved.

The invention belongs to the technical field of biology, and particularly relates to polypeptide for promoting proliferation of mesenchymal stem cells and application of the polypeptide. The amino acid sequence of the polypeptide for promoting proliferation of the mesenchymal stem cells is shown as SEQ ID NO: 1. The active polypeptide for promoting proliferation of the umbilical cord mesenchymal stem cells is obtained by adopting a solid-phase synthesis method. Umbilical cord mesenchymal stem cells obtained by culturing the polypeptide have good adherence and multiplication capacities. In addition, the polypeptide can promote Nrf2 gene expression, so that proliferation of the umbilical cord mesenchymal stem cells is effectively promoted.

The invention discloses a natural product-induced artificial nano-vesicle derived from human umbilical cord mesenchymal stem cells and application of the natural product-induced artificial nano-vesicle in ischemic diseases. The preparation method of the nano vesicle derived from the human umbilical cord mesenchymal stem cells comprises the following steps: S1, inoculating the human umbilical cord mesenchymal stem cells to a 3D microcarrier; then adding traditional Chinese medicine active ingredients to activate the human umbilical cord mesenchymal stem cells, continuing to culture, cracking the microcarrier, and harvesting cells; s2, dispersing the human umbilical cord mesenchymal stem cells obtained in S1 to obtain a suspension, extruding the suspension through a polycarbonate film, and then discarding large particles by adopting a gradient centrifugation method to obtain the nano-vesicles. Compared with naturally secreted exosomes, the exosome has the advantages that the yield is increased, the treatment efficiency is improved, the production cost is reduced, and compared with stem cells, the problems of low transplantation rate and the like are avoided. The stem cells are pretreated based on the traditional Chinese medicine, the vesicles are extracted by utilizing an extrusion method, and the yield and the treatment efficiency of the nano vesicles are remarkably improved.

Disclosed herein are methods for isolation and expansion of umbilical cord-derived mesenchymal stem cells (UC-MSCs) having one or more cell surface markers, and compositions comprising such UC-MSCs. Also disclosed herein are further processing methods for use in connection with the UC-MSCs to isolate extracellular vesicles (EVs) therefrom. Also disclosed herein are lyophilized EVs isolated from the UC-MSCs, and adapted for use as a therapeutic product.

The invention discloses an anti-aging composition and a preparation method thereof, and belongs to the technical field of cosmetics, the anti-aging composition provided by the invention is prepared from the following components in parts by mass: 0.001-0.01 part of freeze-dried powder of secretin of porcine umbilical cord mesenchymal stem cells, 15-20 parts of argania spinosa leaf extract, 10-13 parts of eucheuma gelatinae extract and 1-3 parts of northeast stichopus japonicus adventitious root extract. The anti-aging composition provided by the invention has the effects of resisting aging and improving the migration rate of skin cells, and the whole anti-aging composition is mild and non-irritant; when the anti-aging composition is applied to cosmetics, the anti-aging composition can effectively resist aging, lighten wrinkles, improve skin elasticity and increase the water content of cuticles. In addition, the composition provided by the invention is natural in component source, simple in preparation method and suitable for actual production.